Login to Your Account

Flamel Finds New Basulin Partner, Signs $165M Bristol-Myers Deal

By Brady Huggett

Thursday, August 28, 2003
Flamel Technologies SA again has partnered its recombinant human insulin product, Basulin; this time, signing a deal with Bristol-Myers Squibb Co. valued at up to $165 million. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription